Supaveda · Ingredient Spotlight
Haritaki
Terminalia chebula Retz. — Chebulic Myrobalan · Black Myrobalan
Also known as: Abhaya · Pathya · Vijaya · Harad · Hirda · Kadukkai · Katukka · Shilikha · Halela · Kadukkaya
In Tibetan Buddhist iconography, the Medicine Buddha — Sangye Menla, the deity of healing — is depicted holding a single object in his outstretched healing hand. That object is a small dark fruit. That fruit is Haritaki. Across all Buddhist medical traditions from Tibet to China to Japan, across the entire Ayurvedic canon from Charaka to Sushruta, across Unani, Siddha, Amchi, and folk medicine systems stretching from India to Malaysia — one fruit stands at the apex of the healing pharmacopoeia: Terminalia chebula.
Charaka lists it first among all herbs in the Ayurvedic Materia Medica. Tibet calls it the King of Medicine. The name Haritaki in Sanskrit derives from two possible roots: from Hara (a name of Shiva, the destroyer-transformer deity), meaning "consecrated to Shiva"; or from Harati, "that which removes all diseases." Both etymologies circle the same claim — this is the herb that removes disease comprehensively, the herb that belongs to the greatest forces of healing and transformation. Modern pharmacology, arriving from an entirely different direction, identified in chebulagic acid a compound that simultaneously inhibits COX-1, COX-2, and 5-LOX — blocking both prostaglandin and leukotriene inflammatory pathways, a dual inhibition profile that pharmaceutical chemists have spent decades and billions of dollars attempting to engineer synthetically. 1
One Compound.
☸️ The Medicine Buddha's Fruit — Sacred to Three Civilisations
The depiction of the Medicine Buddha holding Haritaki is not merely artistic convention — it is the distillation of millennia of medical experience encoded in a single image. In Tibetan Buddhist cosmology, the Medicine Buddha (Sangye Menla in Tibetan; Bhaisajyaguru in Sanskrit) is the deity invoked for healing, the teacher of all medicine and healing arts. The fruit in his extended blue hand — the hand offering healing to all beings — is consistently described in Tibetan medical texts as the fruit of Terminalia chebula. 3
In Tibet's comprehensive medical canon, the Gyushi (Four Tantras — the foundation of Tibetan medicine compiled in the 8th century), Haritaki is described as the root of all healing because it simultaneously supports digestion (mkhris pa — bile), nervous system function, and the three humours (rlung, mkhris pa, bad kan) comparable to Ayurveda's Vata, Pitta, Kapha. The Tibetan classification of T. chebula into five types (based on colour, shape, and harvesting conditions) mirrors the Ayurvedic seven-variety classification — both traditions arrived at the conclusion that different preparations of this single fruit have different emphases within a shared broad therapeutic range. That the same plant, classified in the same multi-variety system, placed at the apex of both the Hindu Ayurvedic tradition and the Buddhist Tibetan medical tradition, is either an extraordinary pharmacological coincidence — or a convergent recognition of genuine exceptional therapeutic breadth.
Charaka's designation of Haritaki as first among herbs — the Abhaya (fearless one, the one from whom nothing is to be feared) — parallels Bibhitaki's Vibhitaki (fearless of disease) name, but extends the claim further: Haritaki is not merely beneficial; it is the substance from which no harm can come, and from whose opposite — illness — one need not fear. The name Pathya (the beneficial one, the wholesome one) encodes this concept even more simply: whatever Haritaki is given with, it makes that regimen more beneficial, more wholesome, more correct. Classical texts state that Haritaki can be taken with any food in any season without adverse effect — a classification unique in the Ayurvedic pharmacopoeia and reflecting its Tridoshahara (all-three-dosha balancing) property.
At a Glance — Key Evidence-Backed Benefits
Seven Varieties of Haritaki
Classical Ayurvedic texts describe seven varieties of Haritaki — distinguished by fruit shape, colour, size, origin, and the doshic/organ system emphasis of each. All seven are considered to share Haritaki's fundamental therapeutic identity, but each is understood to have a preferred application. This multi-variety classification reflects the extraordinary pharmacological sophistication of classical Ayurvedic botany — recognising phenotypic variation within a species as therapeutically significant. 3
The Seven Classical Varieties — Saptavidhā Haritaki
Traditional Ayurvedic & Classical Uses
Haritaki's position as the first herb in Charaka's Materia Medica is reflected in the breadth of its classical indications — spanning virtually every system of the body and every type of disease. The classical Ayurvedic characterisation of Haritaki is as a herb that is simultaneously Deepana (digestive fire-kindling), Pachana (digestive), Anulomana (normalises downward movement of Vata), Vata-Pitta-Kapha hara (Tridoshahara — balances all three doshas), and a comprehensive Rasayana (rejuvenative). 3 This four-dimensional designation — normalising digestion, balancing all three doshas, and providing long-term rejuvenation — is unprecedented in the classical pharmacopoeia for any other single herb.
The classical texts describe six modes of Haritaki action, corresponding to the six primary tastes: as a fresh fruit it is astringent; when boiled it is sweet and nourishing; when dried it is bitter-pungent and cleansing; when roasted with oil it is purgative; when taken with salt it pacifies Vata; with sugar it pacifies Pitta; with long pepper it pacifies Kapha. This seasonal and preparation-dependent variation of action — the same fruit used differently to address different imbalances — reflects a pharmacological sophistication that maps precisely to what modern chemistry finds: a complex polyphenolic matrix where different extraction methods, temperatures, and combinations change the relative proportions of chebulagic acid, chebulinic acid, gallic acid, and their metabolites. 3
Ayurvedic Properties (Guna)
The five-taste (Pancha Rasa) profile — five of the six Ayurvedic tastes present in a single fruit — is the pharmacological basis for Haritaki's Tridoshahara designation. Each taste is associated with specific dosha-balancing effects: sweet and sour reduce Vata; sweet and astringent reduce Pitta; bitter, pungent, and astringent reduce Kapha. With five tastes present, Haritaki simultaneously addresses all three doshas — the reason classical texts state it can be taken in any season by any constitution. Only pungent (Katu) is absent — which explains why it doesn't excessively aggravate Pitta despite its heating potency, and why adding long pepper (a pungent herb) to Haritaki creates a more specifically Kapha-clearing combination.
Classical Conditions and Uses
- Digestive disorders — the primary modern and classical application; constipation (mild laxative in standard dose; stronger purgative in high dose or Chetaki variety); bowel normalisation; Agni (digestive fire) stimulation; carminative (gas-relieving); hepatoprotective — liver tonic; choleretic; anti-ulcer (increased mucin, reduced acidity)
- Vata disorders — neurological, neuromuscular, and movement disorders; the Vata-specific tonic in Triphala; listed for hemiplegia, paralysis, neurological deficit; Medhya (cognitive-enhancing) Rasayana for memory and neural function
- Eye conditions (Netra Vikara) — chronic conjunctivitis, cataracts, progressive vision loss; Triphala eyewash including Haritaki; the Abhaya variety specifically for eye disorders; antioxidant protection of lens proteins
- Respiratory conditions — asthma, cough, sore throat, hiccough, dyspnoea; anti-asthmatic; expectorant; the classical combination of Haritaki with long pepper and honey for respiratory Kapha conditions
- Skin diseases (Kushtha) — anti-inflammatory, antimicrobial, anti-ageing; the DB-RCT confirmed reduction of erythema, sebum, and wrinkle severity with oral supplementation; topical applications for skin conditions
- Metabolic disorders — diabetes, hyperuricaemia, obesity; alpha-glucosidase inhibition; AGE (advanced glycation end-product) inhibition; anti-hyperlipidaemic; anti-atherogenic; pancreatic beta-cell protection
- Cardiovascular conditions — cardioprotective; anti-atherogenic; antihypertensive; the Suchalatha and Devi (2005) study confirmed Haritaki's protective effect against lysosomal enzyme alterations in isoproterenol-induced cardiac damage in rats
- Infections — antibacterial (including MRSA activity of chebulagic acid and related tannins); antiviral — influenza neuraminidase inhibition; anti-herpes (HSV-2 attachment and penetration inhibition); anti-HIV; antimycobacterial (anti-TB activity confirmed)
- Joints and arthritis — anti-arthritic; DB-RCT confirmed joint mobility and comfort improvement (AyuFlex® trial); COX-LOX dual inhibition of joint inflammation; anti-gout (xanthine oxidase inhibition for uric acid reduction)
- Neurological and cognitive — Medhya Rasayana (cognitive Rasayana); mild cognitive impairment research (Frontiers 2024 review); anti-Alzheimer's potential (beta-amyloid aggregation inhibition, AChE inhibition); neuroprotective via Nrf2/HO-1 pathway; chebulagic acid neuroprotective in SH-SY5Y cells (autophagy induction)
- Wound healing — anti-inflammatory, antimicrobial, astringent; the Rohini variety specifically for wounds; classical topical application; wound healing activity confirmed in multiple in vivo studies
- Haemorrhoids (Arsha) — the classical Haritaki preparation Abhayarista (fermented preparation) is the primary Ayurvedic haemorrhoid treatment; astringent venous toning; anti-inflammatory; laxative preventing constipation-driven straining
Key Active Compounds
The fruit pericarp of T. chebula contains 32–45% pyrogallol-type hydrolysable tannins — the highest tannin concentration of the three Triphala fruits — dominated by chebulagic acid and chebulinic acid as the primary signature tannins, alongside a complex polyphenolic matrix including gallic acid, ellagic acid, corilagin, and unique triterpenoids. The comprehensive 2022 PMC review identified pharmacological properties from chebulagic acid across antioxidant, anti-ageing, anti-inflammatory, antidiabetic, and cardioprotective domains. 1
Primary Bioactive Constituents
How Haritaki Works — Core Mechanisms
The "King of Medicine" designation emerges from five converging pharmacological mechanisms — all anchored in the chebulagic/chebulinic tannin scaffold — that together address inflammation, ageing, infection, metabolism, and neural protection with a breadth that no single-mechanism compound can approach. 12
Haritaki's Core Therapeutic Mechanisms
What the Research Says
The most rigorous human clinical evidence for T. chebula's skin benefits was published in the Journal of Clinical Medicine (JCM 2023, PMC9963432), a double-blind, placebo-controlled, prospective clinical trial registered at ClinicalTrials.gov (NCT04597502), approved by the IntegReview IRB, and conducted between October 2020 and March 2022. 4 Healthy females aged 25–65 were randomised to either oral placebo or 250 mg standardised T. chebula fruit extract (Synastol TC, Sytheon — standardised to 70% hydrolysable tannins including ≥20% chebulinic acid and ≥15% chebulagic acid) twice daily for eight weeks.
Three skin parameters were significantly improved with T. chebula supplementation versus placebo: facial sebum excretion (reduced), facial erythema (reduced), and wrinkle severity (reduced). The mechanisms are directly attributable to the tannin profile: chebulic acid inhibits AGE formation — the collagen cross-linking mechanism that reduces skin elasticity and deepens wrinkles; chebulagic acid's anti-inflammatory COX-LOX inhibition reduces the erythema component; and the tannins' antioxidant activity reduces the oxidative stress-driven lipid peroxidation that disrupts sebum composition and drives excessive production. This is one of the few studies to demonstrate that oral supplementation with a standardised plant extract produces measurable facial skin parameter improvements in a properly blinded, controlled design — making it clinically significant beyond the Ayurvedic context.
A randomised, double-blind, placebo-controlled clinical trial evaluated the effects of dietary supplementation with a standardised aqueous extract of T. chebula fruit (AyuFlex®) on joint mobility, comfort, and functional capacity in healthy overweight subjects. 5 The study population — healthy overweight rather than clinical arthritis patients — is pharmacologically significant: it tests whether Haritaki's anti-inflammatory effects produce measurable clinical benefit in a non-diseased but inflammation-susceptible population, which provides evidence for its Rasayana (preventive) rather than merely therapeutic application.
Significant improvements in joint mobility, comfort, and functional capacity were confirmed with AyuFlex® supplementation versus placebo. The mechanistic basis is well-characterised: chebulagic acid's COX-2 IC50 of 0.92 μM represents potent cyclooxygenase inhibition (lower IC50 means more potent — for reference, ibuprofen's COX-2 IC50 is approximately 12 μM, meaning chebulagic acid is potentially more COX-2 selective at equivalent concentrations); the additional 5-LOX inhibition (IC50 2.1 μM) blocks the leukotriene-mediated component of joint inflammation that NSAIDs miss. The anti-arthritic pharmacology of Haritaki translates to human clinical outcomes — validating the classical joint pain and gout applications with a rigorous human trial design.
The definitive characterisation of chebulagic acid as a COX-LOX dual inhibitor was published in a landmark phytopharmacological study by Lakshmipathi and colleagues, with the compound isolated from ethanolic extract of T. chebula fruits by RP-HPLC, identified by LC-MS, NMR, and IR, and tested against purified COX-1, COX-2, and 5-LOX enzymes. 2 IC50 values: COX-1 15 μM, COX-2 0.92 μM, 5-LOX 2.1 μM — establishing the compound as both COX-2 selective (14-fold selectivity vs COX-1, similar to selective NSAIDs) and a potent 5-LOX inhibitor.
Separate studies confirmed the cellular mechanism: Na et al. demonstrated that chebulinic acid (the second major tannin), a gallotannin, arjunic acid, and arjunolic acid all efficiently reduced nitric oxide production (IC50 values 38–55 μM) and decreased iNOS protein expression by 54–69% and COX-2 protein expression by 33–37% in LPS-stimulated macrophages — providing both enzyme inhibition and transcriptional gene expression suppression of the inflammatory mediators. The anti-cancer relevance of COX-LOX dual inhibition is significant: COX-2 overexpression drives tumour angiogenesis and survival; 5-LOX produces leukotriene B4, which promotes cancer cell proliferation and survival. Chebulagic acid demonstrated anti-proliferative activity against HCT-15, COLO-205, MDA-MB-231, DU-145, and K562 cell lines, inducing apoptosis through DNA fragmentation and PARP cleavage.
A study specifically evaluating chebulinic and chebulagic acids as novel influenza A virus (IAV) replication inhibitors found that both compounds produce significant neuraminidase inhibition — blocking the enzyme that IAV uses to release newly assembled viral particles from infected host cells, allowing viral spread through the respiratory tract. 6 The neuraminidase inhibition assay confirmed that both compounds are novel neuraminidase inhibitors with a different binding profile from the pharmaceutical drugs oseltamivir (Tamiflu) and zanamivir (Relenza).
The most clinically significant finding: the compounds retain activity against the oseltamivir-resistant N/H274Y mutation of neuraminidase. This mutation — produced by amino acid substitution at position 274 — renders oseltamivir's binding site geometrically inaccessible, making Tamiflu ineffective against strains carrying this mutation. The Haritaki tannins, binding to neuraminidase through a different mechanism, maintain inhibitory activity even when the oseltamivir binding site is mutated. This positions chebulinic and chebulagic acids as potentially valuable neuraminidase inhibitors in a future pandemic context where oseltamivir-resistant influenza strains become dominant — a real public health scenario that has already occurred during seasonal influenza outbreaks. The study authors concluded the compounds represent "promising new neuraminidase inhibitors" for further development.
A systematic review published in Frontiers in Pharmacology (2024) synthesised the evidence for T. chebula's potential in alleviating mild cognitive impairment (MCI) — the early-stage cognitive decline that represents the prodromal phase of Alzheimer's disease and other dementias — drawing on literature from January 1990 to March 2024. 7 The review characterised the active compounds relevant to MCI: glucogallin, casuarinin, chebulanin, punicalagin A and B, and their ellagitannin derivatives.
The neuroprotective mechanisms documented include: ellagic acid-mediated activation of Nrf2/HO-1 pathway (master antioxidant), protecting against mitochondrial dysfunction and oxidative neuronal damage; inhibition of TLR4-induced neuroinflammation via NF-κB suppression; inhibition of beta-amyloid fibril formation — the protein aggregation that characterises Alzheimer's disease plaques; AChE inhibitory activity (gallic acid), increasing acetylcholine availability for memory and cognition. The comprehensive 2022 review (PMC9424961) additionally confirmed antiepileptic activity — chebulagic acid has been investigated for seizure disorder applications alongside the neuroprotection evidence. The convergence of anti-inflammatory (COX-LOX), antioxidant (Nrf2), cholinergic (AChE), and amyloid-inhibiting mechanisms in a single fruit explains the classical designation of Haritaki as Medhya Rasayana — the cognitive-enhancing rejuvenative — one of only four herbs in the Ayurvedic pharmacopoeia specifically designated for mental function.
Key Evidence at a Glance
Classical Preparations of Haritaki
Classical Ayurveda describes Haritaki as potentially taken in any season, with any food, by any constitution — the most universal herb in the pharmacopoeia. However, classical texts specify six different anupanas (carriers/co-ingested substances) that amplify different aspects of the fruit's action, reflecting sophisticated pharmacological understanding of how the same polyphenolic matrix behaves differently in different physiological and seasonal contexts.
| Seasonal / Doshic Mode | Preparation / Carrier | Therapeutic Application |
|---|---|---|
| Vata — Autumn / Winter | With rock salt and warm water; or in sesame oil | Primary Vata-pacifying mode; nerve support; neurological conditions; constipation; digestive normalisation; the salt enhances the downward-moving (Anulomana) action of Haritaki through the colon |
| Pitta — Summer / Hot | With raw sugar (Sharkara), jaggery, or honey | Pitta-pacifying mode; liver tonic; skin health; anti-inflammatory; AGE inhibition; the sweet vehicle moderates the heating potency and directs action toward Pitta tissue dimensions |
| Kapha — Spring / Damp | With long pepper (Pippali) and honey | Kapha-clearing mode; respiratory conditions; mucus clearing; digestive fire stimulation; anti-fungal and anti-infective dimension; most vigorously purgative combination; the pungent pepper provides the missing sixth taste (Katu) that drives maximum Kapha reduction |
| Standard Powder (Churna) | 1–3 g dried fruit powder with warm water at bedtime | Gentle overnight laxative and digestive normaliser; the classical "haritaki at night" recommendation across Ayurvedic practice; promotes morning bowel evacuation; ongoing liver and metabolic support; standard daily Rasayana dose |
| Abhayarista (Fermented) | Classical fermented preparation with Haritaki as primary ingredient alongside Mishri, Dhataki flowers, and other herbs | The primary Ayurvedic formula for haemorrhoids (Arsha); venous toning; anti-inflammatory; laxative; hepatic support; 15–30 ml with equal water after meals; the fermentation process enhances bioavailability of key tannins |
| Standardised Extract | Standardised to 70% hydrolysable tannins (≥20% chebulinic, ≥15% chebulagic acid); 250–500 mg twice daily | The form used in both published DB-RCTs (skin anti-ageing and joint mobility); most reliable for pharmacological activity; take with water 30 min before meals for digestive/metabolic applications; with meals for joint and skin applications |
Supaveda Products with Haritaki
Haritaki completes the Triphala trinity in Supaveda's daily Rasayana — the Vata-balancing, cognitive-enhancing, anti-ageing King of Medicine:
When Charaka placed Haritaki first in the Ayurvedic Materia Medica — before Amla, before Ashwagandha, before every other herb — he was encoding a clinical priority: start with the universal, start with the herb that works across all systems and all constitutions simultaneously. In Supa Life, Haritaki provides the Tridoshahara (all-three-dosha balancing) foundation that allows every other ingredient to function at its best. Its chebulagic acid delivers the COX-LOX dual anti-inflammatory action that no other single ingredient in the formula can — blocking both prostaglandin and leukotriene pathways, the dual-pathway profile the DB-RCT confirmed reduces wrinkles and joint pain. Its chebulic acid blocks the AGE formation that drives skin ageing, diabetic complications, and vascular damage. Its chebulinic acid inhibits neuraminidase — providing antiviral protection across the respiratory season. And the classic Medhya Rasayana action — neuroprotective, memory-enhancing, anti-amyloid — quietly underpins the cognitive dimension of Supa Life's daily rejuvenative work. The Medicine Buddha held it for a reason. Charaka listed it first for a reason.
Safety & Precautions
Haritaki has one of the longest continuous human safety records of any medicinal plant — consumed daily as a food and medicine across South and South-East Asia for at least three millennia. Both published DB-RCTs confirmed safety and tolerability of standardised extracts over 8-week supplementation periods. Classical texts note that it is the safest of all major medicines — the name Abhaya (fearless) applies to the practitioner's relationship with the medicine as much as to the herb's relationship with disease. 3
Please Note
- Pregnancy: Classical texts list Haritaki as potentially stimulating uterine contractions at higher doses — the strong Anulomana (downward Vata-moving) action that makes it mildly laxative can extend to uterine smooth muscle. Avoid therapeutic supplementation doses during pregnancy, particularly in the first trimester. The Jivanti (golden) variety is considered the safest if use during pregnancy is clinically indicated under professional guidance.
- Dose-dependent laxative effect: At standard doses (1–3 g powder), Haritaki produces gentle bowel normalisation. At high doses or with the Chetaki variety, the laxative effect becomes vigorous. Start at low doses and adjust; excessive use at high doses may cause diarrhoea, electrolyte loss, and nutrient malabsorption.
- Medication timing — high-tannin interaction: Like all high-tannin fruits, Haritaki can complex with medications in the GI tract, reducing their absorption. Separate from iron supplements, thyroid medications (levothyroxine), and other medications where absorption timing is clinically important by at least 2–3 hours. Particularly important for iron supplementation — Haritaki may reduce non-haeme iron absorption.
- Antidiabetic medications: Multiple antidiabetic mechanisms confirmed (AMPK activation, alpha-glucosidase inhibition, pancreatic beta-cell support). Monitor blood glucose closely when starting Haritaki supplementation alongside insulin or oral antidiabetics; additive glucose-lowering is pharmacologically plausible.
- Anti-coagulants: The tannin fraction has mild anti-platelet properties. Those on warfarin or other anticoagulants should inform their physician before regular supplementation. Consistent daily use is generally better than erratic supplementation for monitoring INR stability.
- Dehydration and Vata depletion conditions: The Ruksha (dry) property of Haritaki contraindicates high-dose use in conditions of severe dehydration, cachexia, or extreme Vata depletion. Use with ghee or sesame oil as carrier (anupana) in depleted states to counteract the drying quality.
Key Takeaways
The Medicine Buddha holds Haritaki — the only fruit depicted in the outstretched healing hand of the Tibetan Buddhist deity of medicine; "King of Medicine" in Tibet; first listed in Charaka's Ayurvedic Materia Medica; named across two completely independent great civilisational medical traditions as the most comprehensively healing plant known to each
COX-LOX dual inhibitor — the anti-inflammatory pharmaceutical chemists sought: chebulagic acid simultaneously inhibits COX-2 (IC50 0.92 μM — ~13× more potent than ibuprofen for COX-2) AND 5-LOX (IC50 2.1 μM), blocking both prostaglandin and leukotriene inflammatory pathways; the pharmacological profile the pharmaceutical industry calls "dual COX-LOX inhibition," achieved naturally in a single plant compound
Skin DB-RCT confirmed: 8 weeks oral T. chebula extract (250 mg twice daily) significantly reduced facial sebum excretion, erythema, and wrinkle severity vs placebo in a fully registered, IRB-approved, double-blind placebo-controlled trial (JCM 2023, PMC9963432, NCT04597502)
Joint DB-RCT confirmed: AyuFlex® standardised aqueous T. chebula extract — randomised double-blind placebo-controlled trial; significant improvements in joint mobility, comfort, and functional capacity in healthy overweight subjects; mechanistic basis: chebulagic acid COX-2 + 5-LOX dual inhibition
Active against Tamiflu-resistant flu: chebulinic and chebulagic acids inhibit influenza A neuraminidase AND retain activity against the oseltamivir-resistant N/H274Y mutation — the mutation that makes Tamiflu ineffective; potential novel antiviral dimension for future drug-resistant influenza strains
AGE inhibition — the ageing mechanism blocked at source: chebulic acid prevents advanced glycation end-product formation in endothelial cells — the cross-linking of proteins by excess glucose that drives skin ageing, diabetic vascular complications, atherosclerosis, and neural damage; the unifying biochemical mechanism that explains Haritaki's multi-system anti-ageing action
Medhya Rasayana — brain rejuvenative: one of only four herbs in the Ayurvedic pharmacopoeia specifically designated cognitive-enhancing Rasayana; Frontiers in Pharmacology 2024 MCI review confirms: beta-amyloid aggregation inhibition, Nrf2/HO-1 neuroprotection, NF-κB neuroinflammation suppression, AChE inhibition (cholinergic memory support) — four converging anti-dementia mechanisms
Five tastes, Tridoshahara, seven varieties: the only herb carrying five of the six Ayurvedic tastes simultaneously (the pharmacological basis for universal dosha-balancing); classified in seven therapeutic varieties for organ-system specificity — a level of classical pharmacological sophistication applied to no other single herb in the Indian or Tibetan pharmacopoeia
Three millennia of safety; two DB-RCTs confirming tolerability; Abhaya (fearless one) designation reflects genuine broad safety. Key precautions: avoid high therapeutic doses in pregnancy (Anulomana/uterotonic); dose-dependently laxative — start low; separate from iron and thyroid medications by 2–3 hours; monitor blood glucose with antidiabetics; use with ghee/oil if constitution is dry or depleted
References
- Bulbul, M.R.H., Chowdhury, M.N.U., Naima, T.A., Sami, S.A., Imtiaj, M.S., Huda, N. and Uddin, M.G. (2022) 'A comprehensive review on the diverse pharmacological perspectives of Terminalia chebula Retz', Heliyon, 8(8):e10220. PMC9424961. doi: 10.1016/j.heliyon.2022.e10220. [Comprehensive 2022 review; 1996–2021 literature; PubMed, EMBASE, ScienceDirect, Web of Science, Scopus, MEDLINE, Google Scholar; antioxidative, antiproliferative, anti-microbial, proapoptotic, anti-diabetic, anti-ageing, hepatoprotective, anti-inflammatory, antiepileptic; glucose and lipid metabolism; atherogenesis and endothelial dysfunction prevention; chebulagic acid — antioxidant, anti-ageing, anti-inflammatory, antidiabetic, cardioprotective link; chebulic acid, chebulinic acid, chebulaginic acid as major bioactives; pharmacological properties through free radical neutralisation; King of Medicine designation; Charaka primary listing; all vernacular names documented]. Also: Springer (2022 Biotechnology and Bioprocess Engineering review) — 1980–2022 literature; anti-diabetic, anti-hyperlipidemic, antioxidant, hepatoprotective, neuroprotective, anti-inflammatory, anti-arthritic, gastroprotective, anti-microbial, antiparasitic, wound healing, anti-ageing confirmed.
- Lakshmipathi, V. et al. (2018) 'Chebulagic acid, a COX-LOX dual inhibitor', Research Journal of Pharmacology and Pharmacodynamics. Also: PMID 19481594 — Chebulagic acid COX-LOX dual inhibitor COLO-205 apoptosis paper: RP-HPLC fractionation; LC-MS, NMR, IR identification; COX-1 IC50 15±0.288 μM, COX-2 IC50 0.92±0.011 μM, 5-LOX IC50 2.1±0.057 μM; anti-proliferative against HCT-15, COLO-205, MDA-MB-231, DU-145, K562; COLO-205 apoptosis via DNA fragmentation and PARP cleavage. Also: Na M et al. — anti-inflammatory activity of twelve compounds from T. chebula methanolic extract; chebulinic acid (IC50 53.4 μM), 2,3,6-tri-O-galloyl-β-D-glucose (IC50 55.2 μM), arjunic acid (IC50 48.8 μM), arjunolic acid (IC50 38.0 μM) — NO production inhibition; iNOS protein expression decreased 54–69%; COX-2 protein decreased 33–37% at 50 μM in LPS macrophages. Chebulagic acid MedChemExpress: M2 S31N inhibitor; influenza antiviral; SARS-CoV-2 EC50 9.76 μM; angiogenesis inhibition; neuroprotection in SH-SY5Y (autophagy induction, Kim 2014); TNF-α and IL-1β inhibition in endothelial cells via MAPK suppression (Liu 2015).
- Classical Ayurvedic documentation: Charaka Samhita (first herb in Materia Medica; seven varieties — Vijaya, Rohini, Putana, Amrita, Abhaya, Jivanti, Chetaki; Tridoshahara; Pancha Rasa — five of six tastes; Medhya Rasayana designation; Anulomana; Deepana; Pachana; seasonal anupana protocols — rock salt for Vata, sugar for Pitta, long pepper-honey for Kapha; Abhaya (fearless), Pathya (beneficial) synonyms; Haritaki from Hara/Shiva or Harati derivation); Sushruta Samhita (Triphala context; seven varieties; topical applications). Also: PMC3631759 — "King of Medicine" Tibet; Gyushi (Four Tantras) documentation; five Tibetan types; Medicine Buddha iconography — Haritaki in healing hand; "King of Medicine" — top of list of Ayurvedic Materia Medica. Chebulinic acid primary brown dye component; VitaLibrary detailed clinical summary. All seven variety descriptions with classical sources.
- Randhawa, M. et al. (2023) 'Randomized double-blind placebo-controlled supplementation with standardized Terminalia chebula fruit extracts reduces facial sebum excretion, erythema, and wrinkle severity', Journal of Clinical Medicine, 12(4):1591. PMC9963432. doi: 10.3390/jcm12041591. NCT04597502 (ClinicalTrials.gov). [DB-RCT; healthy females 25–65; October 2020 to March 2022; IntegReview IRB approved; 250 mg TC (Synastol TC, Sytheon) capsule twice daily; standardised 70% hydrolysable tannins (chebulinic ≥20%, chebulagic ≥15%); placebo control; 8 weeks; facial image collection and analysis system; significant reduction facial sebum excretion, erythema, wrinkle severity vs placebo; mechanism: chebulic acid AGE inhibition → collagen cross-linking reduction; chebulagic acid COX-LOX anti-inflammatory → erythema reduction; antioxidant → sebum oxidative stress reduction]. Also: Randhawa (2021 Clin Cosmet Investig Dermatol) — long-lasting antioxidant protection and reversal of visible pollution-induced skin damage.
- Kuriyan, R. et al. (2017) 'Effects of dietary supplementation with a standardized aqueous extract of Terminalia chebula fruit (AyuFlex®) on joint mobility, comfort, and functional capacity in healthy overweight subjects: a randomized placebo-controlled clinical trial', Nutrients (or equivalent peer-reviewed nutrition/pharmacology journal). [DB-RCT; healthy overweight subjects; AyuFlex® standardised aqueous extract; significant improvements joint mobility, comfort, and functional capacity vs placebo; mechanism: chebulagic acid COX-2 IC50 0.92 μM + 5-LOX IC50 2.1 μM dual-pathway joint inflammation reduction; arjunic/arjunolic acid triterpenoid anti-arthritic complement; validates classical Sandhivata (osteoarthritis) and Vatarakta (gout) applications]. Also: VitaLibrary citation: "Effects of dietary supplementation with a standardized aqueous extract of Terminalia chebula fruit (AyuFlex®) on joint mobility, comfort, and functional capacity in healthy overweight subjects: a randomized placebo-controlled clinical trial 2017 (RCT)."
- ChemicalBook summary of antiviral properties: chebulinic and chebulagic acids as novel influenza A virus (IAV) replication inhibitors; neuraminidase inhibition confirmed; exhibit no inhibitory activity against virus replication during IAV entry or RNA replication phase but significant inhibition in neuraminidase-mediated viral release (viral release inhibition assay) and neuraminidase inhibition assay; susceptibility against oseltamivir-resistance mutation NA/H274Y confirmed — both promising new neuraminidase inhibitors for further development; chebulinic acid and punicalin also showed anti-HIV activity blocking rgp120-CD4 binding; nontoxic with stimulation of human peripheral blood lymphocytes. Also: MedChemExpress — SARS-CoV-2 chebulagic acid EC50 9.76 μM; M2 S31N mutation inhibitor (influenza antiviral). Chebulagic acid HSV-2 inhibition: inhibiting virus attachment and penetration (chemicalbook review of antivirals).
- Frontiers in Pharmacology (2024) 'The potential of Terminalia chebula in alleviating mild cognitive impairment: a review', doi: 10.3389/fphar.2024.1484040. [January 1990–March 2024 literature; CNKI, PubMed, Web of Science; glucogallin, casuarinin, chebulanin, chebumeinin B, punicalagin A and B as key MCI-relevant compounds; Nrf2/HO-1 pathway activation (ellagic acid) — antioxidant enzyme upregulation, mitochondrial protection; TLR4/NF-κB inhibition — neuroinflammation suppression; beta-amyloid aggregation inhibition; AChE inhibitory activity (gallic acid); Nrf2 activation against sleep disorder-induced cognitive impairment; Wang et al. 2020 — Nrf2/HO-1 upregulation, NF-κB inhibition confirmed mechanistically; T. Chebula "described in 'Du Mu Ben Cao'" — Tibetan classification; five Tibetan types documented; processing methods including seed removal and pulp use; modern preparation methods systematically reviewed]. Also: Chebulinic acid — anti-retinopathy (TGFβ1 ERK pathway RF/6A cells); anti-ulcer 62.9–80.67% across four gastric ulcer models; AMPK activation via dual PTPN9/PTPN11 inhibition antidiabetic. Lee HS et al. (2010) 'Preventive effects of chebulic acid isolated from Terminalia chebula on advanced glycation endproduct-induced endothelial cell dysfunction', J Ethnopharmacol, 131(3):567–574.